- Home
- SPT vs MNKD Comparison
SPT vs MNKD Comparison
Compare SPT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- MNKD
- Stock Information
- Founded
- SPT 2010
- MNKD 1991
- Country
- SPT United States
- MNKD United States
- Employees
- SPT N/A
- MNKD N/A
- Industry
- SPT Computer Software: Prepackaged Software
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- MNKD Health Care
- Exchange
- SPT Nasdaq
- MNKD Nasdaq
- Market Cap
- SPT 1.2B
- MNKD 1.4B
- IPO Year
- SPT 2019
- MNKD 2004
- Fundamental
- Price
- SPT $20.32
- MNKD $3.77
- Analyst Decision
- SPT Buy
- MNKD Buy
- Analyst Count
- SPT 13
- MNKD 4
- Target Price
- SPT $31.69
- MNKD $9.75
- AVG Volume (30 Days)
- SPT 642.1K
- MNKD 2.8M
- Earning Date
- SPT 07-31-2025
- MNKD 08-06-2025
- Dividend Yield
- SPT N/A
- MNKD N/A
- EPS Growth
- SPT N/A
- MNKD 228.27
- EPS
- SPT N/A
- MNKD 0.10
- Revenue
- SPT $418,413,000.00
- MNKD $297,595,000.00
- Revenue This Year
- SPT $12.32
- MNKD $13.72
- Revenue Next Year
- SPT $11.90
- MNKD $15.21
- P/E Ratio
- SPT N/A
- MNKD $36.44
- Revenue Growth
- SPT 17.79
- MNKD 32.50
- 52 Week Low
- SPT $18.52
- MNKD $3.63
- 52 Week High
- SPT $39.75
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- SPT 41.85
- MNKD 38.22
- Support Level
- SPT $19.32
- MNKD $3.70
- Resistance Level
- SPT $20.72
- MNKD $4.00
- Average True Range (ATR)
- SPT 0.66
- MNKD 0.16
- MACD
- SPT -0.08
- MNKD 0.01
- Stochastic Oscillator
- SPT 30.58
- MNKD 16.47
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.